Acquisition leverage Potential cross-sell and integration opportunities with Unchained Labs following the 2022 acquisition, focusing on NanoView's ExoView platforms to expand customers in BI/EV biology and biologics development.

Exosome platform Target research institutions and biotechs focused on extracellular vesicles, exosomes, and viral characterization to expand adoption of ExoView R200 and related high-throughput, cost-efficient analysis solutions.

SB and leadership Engage via Scientific Advisory Board affiliations and collaborations with academic centers (e.g., BIDMC) to secure pilot studies and advisory roles that can drive early access programs and credibility in EV biomarker research.

Early-stage focus Small to mid-size biotech firms with sub-$1M revenue present a high-potential market for scalable, high-throughput exosome analysis platforms to accelerate diagnostics and precision medicine research.

Hybrid platform upsell Promote bundled offerings combining ExoView platforms with cloud analytics, data storage, and workflow automation on AWS and related tech stack to improve researcher efficiency and data management.